AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02544880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tadalafil Placebo
Description: Placebo tablets mimicking Tadalafil administered by mouth. On course 1, Tadalafil Placebo will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil placebo will be administered daily for 14 consecutive days. No Tadalafil Placebo will be provided on Course 5.
Study NCT02544880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-MUC1 Vaccine Placebo
Description: Placebo for Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Placebo for Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5..
Study NCT02544880 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Treatment
Description: Treatment according to prescribed standard of care regimen.
Study NCT02544880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Influenza Vaccine Placebo
Description: Placebo for Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Placebo for Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
Study NCT01955395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response Resiliency Program (3RP)
Description: The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
Study NCT02639403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal three-dimensional Radiotherapy
Description: Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
Study NCT03037606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabelis DDR 50 mg Capsules
Description: Rabelis DDR 50 mg Capsules once daily for seven days.
Study NCT03037606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pariet 20 mg Enteric Coated Tablets
Description: Pariet 20 mg Enteric Coated Tablets once daily for seven days.
Study NCT03406715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (BMS-936558) is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. Induction Immunotherapy Phase (4 x 21 days cycles): Nivolumab on Day 1 of each cycle for 4 cycles. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: Nivolumab only on Day 1 of every 4 week period. Participants will continue to receive Nivolumab only on Day 1 of each additional 4 week period that they take part until their disease progresses. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
Study NCT03406715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is an antibody (a type of human protein) that is approved to treat patients with metastatic melanoma. In this study, the use of ipilimumab is investigational. Induction Immunotherapy Phase (4 x 21 days cycles): Ipilimumab on Day 1 of each cycle for 4 cycles. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
Study NCT03406715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell based p53 Vaccine
Description: Dendritic Cell based p53 Vaccine (Ad.p53-DC). The p53 vaccine will be made by inserting the p53 gene (a gene is a hereditary unit of all living organism within a cell) into a subset of the participant's own white blood cells. The insertion of the gene into their white blood cells will occur in the laboratory, after their cells have been extracted from their body through a procedure called leukopheresis (similar to dialysis). Induction Immunotherapy Phase (4 x 21 day cycles): Participants will receive the p53 vaccine on Days 1 and 15 of cycle 1 and then again on Day 8 of Cycle 2. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: p53 vaccine three additional times (every 4 weeks over a 12 week period).
Study NCT00910728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480
Description: Oral capsule 2.5 mg, 10 mg and 40 mg
Study NCT00578604 — intervention group
Intervention type: DEVICE
Intervention: diffuse near infrared spectroscopy measurements
Description: Measure blood flow to diabetic wounds
Study NCT04297293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)
Study NCT04521920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study NCT02440204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
Study NCT02440204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
Study NCT02440204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
Study NCT04521920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP
Description: Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study NCT00858936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-1001
Description: 6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
Study NCT02204423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-Radial Percutaneous Coronary Intervention (TR-PCI)
Study NCT01545297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
Study NCT01545297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
Study NCT01545297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
Study NCT00858936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
Study NCT00611988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-managed walking
Description: The intervention includes individual therapy, group reinforcement, and follow-up phone contact
Study NCT02956746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN023
Description: The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
Study NCT02956746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imovax
Description: Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
Study NCT02956746 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imovax
Description: Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
Study NCT02956746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RabAvert
Description: Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
Study NCT02956746 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RabAvert
Description: Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
Study NCT02956746 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HyperRAB ST (human rabies immune globulin)
Description: The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
Study NCT00976105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem or placebo - Hypnotic drug given for sleep disorders
Description: The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
Study NCT00976105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1521498 or placebo
Description: The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
Study NCT03640403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
Study NCT03640403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-amodiaquine
Description: Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
Study NCT00611988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Attention control group will receive routine follow-up phone calls
Study NCT00756678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubricant Eye Drops (Optive™)
Description: 1 drop in both eyes as needed for 7 days'
Study NCT00756678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubricating Eye Drops (blink® Tears)
Description: 1 drop in both eyes as needed for 7 days
Study NCT03006081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept injection
Description: Six number of injections at baseline, 1M, 2M, 3M, 4M, and 5M
Study NCT00829218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glutamate additive-free diet
Description: All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
Study NCT00829218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glutamate additive-free diet
Description: All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
Study NCT00829218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo diet
Description: Juice with nothing added.
Study NCT01110226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KML-001
Description: KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off.
Study NCT02491047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BonyPid-1000
Description: BonyPid-1000 implantation concomitantly to standard of care (SOC) treatment
Study NCT02491047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) treatment
Description: Standard of Care (SOC) treatment only
Study NCT01845831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Bolus
Description: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
Study NCT02491047 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC) treatment
Description: Standard of Care (SOC) treatment only
Study NCT01845831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Sitagliptin
Description: Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
Study NCT03577834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: liquid vinegar
Description: 6% red wine vinegar (2 tablespoons providing 1.7 g acetic acid)
Study NCT03577834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vinegar pill
Description: Apple Cider Vinegar Tablets (1 tablet providing 0.0225 g acetic acid)
Study NCT01108328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
Study NCT01108328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
Study NCT01244035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
Study NCT01244035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
Study NCT01244035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
Study NCT01244035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
Study NCT01244035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
Study NCT01244035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
Study NCT01292122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCT-01
Description: Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
Study NCT03032419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV-Al SSI
Description: 3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
Study NCT03032419 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV SSI
Description: 3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
Study NCT00330304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: isoniazid 10mg/kg orally, daily, for study period
Study NCT00330304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Description: Cotrimoxazole given 3 times a week or daily, orally, for study period
Study NCT00330304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cotrimoxazole
Description: Cotrimoxazole given 3 times a week or daily, orally, for study period
Study NCT00330304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: Isoniazid, 10mg/kg daily for study period
Study NCT00330304 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet identicle in appearance to intervention: isoniazid table
Study NCT00594607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AN69ST dialysis membrane
Description: AN69ST is the filter that the blood goes through during hemodialysis
Study NCT00594607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fx8 (Fresenius)
Description: Polysulphone dialysis membrane
Study NCT01542463 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Prescribed at the discretion of the physician
Study NCT01047917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation DVD
Description: Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
Study NCT01486355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Description: Edmonston-Zagreb measles vaccine
Study NCT05147753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: 0.6 mg moxonidine daily
Study NCT03275090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smoflipid ®
Study NCT00855777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: etoricoxib 120 mg/day for 3 days
Study NCT00855777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: ibuprofen 1,800 mg/day for 3 days
Study NCT03389698 — intervention group
Intervention type: DEVICE
Intervention: GRASP Dynamic Contrast-Enhanced (DCE) MRI
Description: Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.
Study NCT03389698 — intervention group
Intervention type: DEVICE
Intervention: 3T Brain Scan
Description: Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.
Study NCT03389698 — intervention group
Intervention type: DRUG
Intervention: Gadolinium-based Contrast Agent (GBCA) for MRI
Description: Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.
Study NCT01160393 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Miniaturized bypass system
Description: Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
Study NCT03180580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEAL guideline and healthy tiffin box intervention
Description: Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children.
Study NCT04648917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeic acid
Description: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight >50kg, 200mg per time, weight \< or =50kg, 100mg per time)